When did West announce its current share repurchase program?

West announced its share repurchase program in mid-February 2026. The company reported executing under this program throughout the first half of 2026, purchasing 1.8 million shares through June 30, 2026.

What was the average price paid per share in the H1 2026 repurchase?

West repurchased shares at an average price of $258.03 per share during the first six months of 2026. This represented a total investment of $454.3 million for the 1.8 million shares acquired.

How did the buyback affect West's share count?

The 1.8 million share repurchase in H1 2026 reduced diluted average shares outstanding to 71.9 million from 72.8 million in the prior-year period, a reduction of approximately 1.2%. This contributed to mechanically accretive earnings per share.

Does the earnings release disclose how much authorization remains?

No, the July 23, 2026 earnings release does not disclose the remaining dollar amount or share authorization under the February 2026 program. Investors would need to reference the company's subsequent 10-Q or proxy statement for updated authorization details.

How does the buyback compare to West's free cash flow generation?

West generated $128.0 million in free cash flow during H1 2026 (operating cash flow of $213.9 million minus capex of $85.9 million), while deploying $454.3 million on share repurchases. This indicates the company used cash on hand or borrowings to fund the buyback beyond the period's free cash generation.

What execution mechanism does West use for its buybacks?

West executes share repurchases under Rule 10b-18 open-market purchase procedures, which is the standard mechanism allowing companies to repurchase shares during trading windows with safe-harbor protections under SEC regulations.

WST 8-K Filed 2026-07-23 Execution disclosure

West Pharmaceutical repurchased 1.8M shares for $454M in H1 2026

Execution update: Company repurchased shares at $258.03 average price under February 2026 authorization

Shares repurchased1.8M

Avg price paid$258.03

MechanismRule 10b-18 open-market purcha

What the filing says

West Pharmaceutical Services, Inc. (NYSE: WST) reported that during the first six months of 2026, it repurchased 1.8 million shares for $454.3 million at an average price of $258.03 per share under its share repurchase program announced in mid-February 2026. This execution activity was disclosed in the company's second-quarter 2026 earnings release filed as an 8-K on July 23, 2026.

The repurchase program was executed under standard Rule 10b-18 open-market purchase procedures, as is customary for West's buyback activity. The $454.3 million deployed represents a significant allocation of free cash flow in the period; the company generated $128.0 million in free cash flow during the same six-month interval (operating cash flow of $213.9 million less capital expenditures of $85.9 million).

The share reduction lowered the company's diluted average shares outstanding to 71.9 million for the six-month period ended June 30, 2026, compared to 72.8 million in the prior-year period. West did not disclose the remaining authorization amount under the February 2026 program in this earnings release.

During the first six months of 2026, the Company repurchased 1.8 million shares for $454.3 million at an average price of $258.03 per share under its share repurchase program that was announced in mid-February 2026. — WEST PHARMACEUTICAL SERVICES INC 8-K filing · View on SEC EDGAR →

What this means

West Pharmaceutical's H1 2026 buyback was executed at an average price of $258.03 per share, reducing share count by approximately 2.5% relative to the prior-year period. The $454.3 million repurchase was funded primarily from operating cash flow and represents a material allocation of capital alongside organic growth investments (capital spending of $85.9 million in the period). This execution is consistent with the company's capital allocation policy, which balances shareholder returns through both dividends (third-quarter 2026 dividend declared at $0.22 per share) and opportunistic buybacks. The repurchase contributed to a reduction in diluted shares from 72.8 million to 71.9 million year-over-year, providing a modest accretion to earnings per share mechanically.

Frequently asked questions

When did West announce its current share repurchase program?: West announced its share repurchase program in mid-February 2026. The company reported executing under this program throughout the first half of 2026, purchasing 1.8 million shares through June 30, 2026.
What was the average price paid per share in the H1 2026 repurchase?: West repurchased shares at an average price of $258.03 per share during the first six months of 2026. This represented a total investment of $454.3 million for the 1.8 million shares acquired.
How did the buyback affect West's share count?: The 1.8 million share repurchase in H1 2026 reduced diluted average shares outstanding to 71.9 million from 72.8 million in the prior-year period, a reduction of approximately 1.2%. This contributed to mechanically accretive earnings per share.
Does the earnings release disclose how much authorization remains?: No, the July 23, 2026 earnings release does not disclose the remaining dollar amount or share authorization under the February 2026 program. Investors would need to reference the company's subsequent 10-Q or proxy statement for updated authorization details.
How does the buyback compare to West's free cash flow generation?: West generated $128.0 million in free cash flow during H1 2026 (operating cash flow of $213.9 million minus capex of $85.9 million), while deploying $454.3 million on share repurchases. This indicates the company used cash on hand or borrowings to fund the buyback beyond the period's free cash generation.
What execution mechanism does West use for its buybacks?: West executes share repurchases under Rule 10b-18 open-market purchase procedures, which is the standard mechanism allowing companies to repurchase shares during trading windows with safe-harbor protections under SEC regulations.

execution rule-10b-18 mega-cap healthcare-services open-market-purchases

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.